Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer

被引：4

作者：

Shiihara, Jun ^{[1
]}

Ohyanagi, Fumiyoshi ^{[1
,2
]}

Amari, Hikari ^{[1
]}

Toda, Minemichi ^{[1
]}

Tahara, Hiroki ^{[1
]}

Yuzawa, Motoi ^{[1
]}

Maeda, Yuki ^{[1
]}

Nomura, Motoko ^{[1
]}

Mizushina, Yoshiko ^{[1
,3
]}

Nagai, Yoshiaki ^{[1
]}

Ohta, Hiromitsu ^{[1
]}

Yamaguchi, Yasuhiro ^{[1
]}

机构：

[1] Jichi Med Univ, Clin Dept Internal Med, Div Resp Med, Saitama Med Ctr, Saitama, Japan

[2] Saitama Canc Ctr, Div Resp Med, Saitama, Japan

[3] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan

来源：

THORACIC CANCER | 2021年 / 12卷 / 17期

关键词：

alectinib; anaplastic lymphoma kinase; lung cancer; squamous cell cancer; MOLECULAR TESTING GUIDELINE; OPEN-LABEL; CRIZOTINIB; CARCINOMA; ASSOCIATION; GEFITINIB; PATHOLOGY; SELECTION; COLLEGE;

D O I：

10.1111/1759-7714.14092

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene. The patient was treated with the ALK-TKI alectinib as first-line regimen and achieved a dramatic response without severe adverse events, demonstrating alectinib as a therapeutic option for patients with ALK-positive squamous cell carcinoma.

引用

页码：2420 / 2423

页数：4

共 50 条

[1] Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
Tanaka H.
Taima K.
Morimoto T.
Nakamura K.
Tanaka Y.
Itoga M.
Takanashi S.
Okumura K.
[J]. BMC Research Notes, 9 (1)
[2] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
Imanishi, Naoko
Yoneda, Kazue
Taira, Akihiro
Ichiki, Yoshinobu
Sato, Naoko
Hisaoka, Masanori
Tanaka, Fumihiro
[J]. SURGICAL CASE REPORTS, 2018, 4
[3] Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
Naoko Imanishi
Kazue Yoneda
Akihiro Taira
Yoshinobu Ichiki
Naoko Sato
Masanori Hisaoka
Fumihiro Tanaka
[J]. Surgical Case Reports, 4 (1)
[4] ALK-rearranged squamous cell carcinoma of the lung
Takanashi, Yusuke
Tajima, Shogo
Matsuura, Shun
Koyama, Shin
Takahashi, Tsuyoshi
Neyatani, Hiroshi
[J]. RESPIROLOGY CASE REPORTS, 2015, 3 (03): : 105 - 107
[5] ALK-rearranged squamous cell lung cancer: a case report
Zhang, Quan
Wang, Jinghui
Zhang, Shucai
[J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 2195 - 2198
[6] ALK-rearranged squamous cell carcinoma of the lung
Meng, Qiyi
Dong, Yujie
Tao, Hong
Shi, Liang
Tong, Li
Tang, Junfang
Zhang, Shucai
Liu, Zhe
[J]. THORACIC CANCER, 2021, 12 (07) : 1106 - 1114
[7] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
Mamesaya, Nobuaki
Nakashima, Kazuhisa
Naito, Tateaki
Nakajima, Takashi
Endo, Masahiro
Takahashi, Toshiaki
[J]. BMC CANCER, 2017, 17
[8] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
Nobuaki Mamesaya
Kazuhisa Nakashima
Tateaki Naito
Takashi Nakajima
Masahiro Endo
Toshiaki Takahashi
[J]. BMC Cancer, 17
[9] Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
Zhu, Viola
Ou, S. H.
[J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 509 - 514
[10] The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
Srinivasamaharaj, Srividya
Salame, Bilal Khameze
Rios-Perez, Jorge
Kloecker, Goetz
Perez, Cesar A.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (12) : 1227 - 1233

← 1 2 3 4 5 →